Ratings Carl Zeiss Meditec AG OTC Markets

Equities

CZMWF

DE0005313704

Market Closed - OTC Markets Other stock markets 08:58:30 18/06/2024 pm IST			5-day change	1st Jan Change
71.43 ^USD	-19.83%		-23.11%	-33.42%

19/06	CARL ZEISS MEDITEC : CZM’s eye attractiveness fades
18/06	CARL ZEISS MEDITEC : CZM’s eye attractiveness fades

Strengths

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company benefits from high valuations in earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
CARL ZEISS MEDITEC AG	-33.42%	6.38B	-
THERMO FISHER SCIENTIFIC	+7.23%	217B	B
DANAHER CORPORATION	+11.31%	191B	B-
INTUITIVE SURGICAL, INC.	+28.94%	154B	B-
BOSTON SCIENTIFIC CORPORATION	+32.00%	112B	A-
SIEMENS HEALTHINEERS AG	-0.46%	62.84B	A-
EDWARDS LIFESCIENCES CORPORATION	+16.09%	53.34B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+0.94%	48.83B	B+
AGILENT TECHNOLOGIES, INC.	-2.97%	39.36B	A
GE HEALTHCARE TECHNOLOGIES INC.	+1.23%	35.73B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes